| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
88,880,000 as of 12/31 |
| Market
Cap: |
1.11(B) |
| Last
Volume: |
2,587,345 |
Avg
Vol: |
3,435,302 |
| 52
Week Range: |
$10.2 - $29.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Vivus is a biopharmaceutical company engaged in the development and commercialization of therapeutic drugs for underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. Co.'s investigational drug pipeline includes two late-stage clinical investigational drug candidates: Qnexa for the treatment of obesity, diabetes and obstructive sleep apnea; and Avanafil the treatment of erectile dysfunction. In addition, Co. has licensed the rights to other investigational drug candidates to treat various diseases and medical conditions. Co. also sponsors early stage clinical trials at various research institutions.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$538,649 |
$538,649 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
863,241 |
2,056,014 |
| Total Sell Value |
$0 |
$0 |
$22,888,900 |
$46,845,787 |
| Total People Sold |
0 |
0 |
10 |
11 |
| Total Sell Transactions |
0 |
0 |
21 |
39 |
| End Date |
2013-02-17 |
2012-11-16 |
2012-05-18 |
2011-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Plutzky Jorge Md |
Director |
|
2013-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Carroll J Martin |
Director |
|
2013-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Wilson Robert N |
Director |
|
2013-04-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,650 |
|
-3% |
|
Wilson Robert N |
Director |
|
2013-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
25,650 |
|
- |
|
Logan Mark B |
Director |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,125 |
74,125 |
|
- |
|
Mario Ernest |
Director |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,125 |
66,125 |
|
- |
|
Shortliffe Linda M Dairiki |
Director |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,125 |
26,125 |
|
- |
|
Casamento Charles J |
Director |
|
2013-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,125 |
87,125 |
|
- |
|
Mario Ernest |
Director |
|
2012-08-20 |
4 |
B |
$20.75 |
$103,750 |
D/D |
5,000 |
45,000 |
2.39 |
-31% |
|
Casamento Charles J |
Director |
|
2012-08-20 |
4 |
S |
$20.63 |
$165,060 |
D/D |
(8,000) |
66,000 |
|
31% |
|
Casamento Charles J |
Director |
|
2012-08-20 |
4 |
OE |
$5.69 |
$45,520 |
D/D |
8,000 |
74,000 |
|
- |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-14 |
4 |
OE |
$4.25 |
$82,820 |
D/D |
18,000 |
13,000 |
|
- |
|
Logan Mark B |
Director |
|
2012-08-14 |
4 |
S |
$23.13 |
$1,152,169 |
D/D |
(49,816) |
53,000 |
|
45% |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-14 |
4 |
S |
$22.50 |
$409,000 |
D/D |
(18,000) |
5,000 |
|
45% |
|
Logan Mark B |
Director |
|
2012-08-14 |
4 |
OE |
$4.25 |
$280,838 |
D/D |
49,816 |
61,000 |
|
- |
|
Logan Mark B |
Director |
|
2012-08-13 |
4 |
S |
$21.81 |
$396,580 |
D/D |
(18,184) |
53,000 |
|
38% |
|
Logan Mark B |
Director |
|
2012-08-13 |
4 |
OE |
$4.25 |
$77,282 |
D/D |
18,184 |
71,184 |
|
- |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-13 |
4 |
S |
$22.00 |
$440,000 |
D/D |
(20,000) |
5,000 |
|
38% |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-13 |
4 |
OE |
$4.25 |
$85,000 |
D/D |
20,000 |
25,000 |
|
- |
|
Mario Ernest |
Director |
|
2012-08-10 |
4 |
B |
$21.50 |
$107,500 |
D/D |
5,000 |
40,000 |
2.39 |
-39% |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-10 |
4 |
OE |
$4.23 |
$105,750 |
D/D |
25,000 |
30,000 |
|
- |
|
Shortliffe Linda M Dairiki |
Director |
|
2012-08-10 |
4 |
S |
$21.50 |
$537,500 |
D/D |
(25,000) |
5,000 |
|
39% |
|
Mario Ernest |
Director |
|
2012-08-09 |
4 |
B |
$21.83 |
$327,399 |
D/D |
15,000 |
35,000 |
2.39 |
-37% |
|
Miller Michael Patrick |
Chief Commercial Officer |
|
2012-07-18 |
4 |
AS |
$30.36 |
$759,000 |
D/D |
(25,000) |
7,943 |
|
-61% |
|
Miller Michael Patrick |
Chief Commercial Officer |
|
2012-07-18 |
4 |
OE |
$10.19 |
$254,750 |
D/D |
25,000 |
32,943 |
|
- |
|
239 Records found
|
|
Page 1 of 10 |
|
|